Drug Patents owned by United Therap
1. Drug name - ORENITRAM
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 7 months from now) | |
| US7417070 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2026
(3 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(6 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(6 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(6 years from now) | |
| CN101265226A | UNITED THERAP | Compound And Method For Delivery Of Prostacyclin Analogueue |
May, 2024
(1 year, 7 months from now) | |
| CN101780092B | UNITED THERAP | Compounds And Method For Releasing Prostacyclin Analogue |
May, 2024
(1 year, 7 months from now) | |
| CN100558351C | UNITED THERAP | Composition And Method For Releasing Prostacyclin Analogue |
May, 2024
(1 year, 7 months from now) | |
| CN101265226B | UNITED THERAP | Composition And Method For Releasing Prostacyclin Analogue |
May, 2024
(1 year, 7 months from now) | |
| CN101780092A | UNITED THERAP | Compound And Method For Releasing Prostacyclin Analogue |
May, 2024
(1 year, 7 months from now) | |
| CN1822826A | UNITED THERAP | Compounds And Method For Releasing Prostacyclin Analogue |
May, 2024
(1 year, 7 months from now) | |
| CN101903324B | UNITED THERAP | A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method |
Dec, 2028
(6 years from now) | |
| CN101903324A | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| CN103274926A | UNITED THERAP | Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| CN103274926B | UNITED THERAP | An Improved Method For Preparing Active Components In The Curved Remodulin |
Dec, 2028
(6 years from now) | |
| IN200502621P2 | UNITED THERAP | An Oral Pharmaceutical Composition |
May, 2024
(1 year, 7 months from now) | |
| IN247151B | UNITED THERAP | An Oral Pharmaceutical Composition |
May, 2024
(1 year, 7 months from now) | |
| IN201003640P4 | UNITED THERAP | An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| IN287697B | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| EP1628654B1 | UNITED THERAP | Compounds And Methods For Delivery Of Prostacyclin Analogs |
May, 2024
(1 year, 7 months from now) | |
| EP1628654A4 | UNITED THERAP | Compounds And Methods For Delivery Of Prostacyclin Analogs |
May, 2024
(1 year, 7 months from now) | |
| EP2792353A3 | UNITED THERAP | Compounds And Methods For Delivery Of Prostacyclin Analogs |
May, 2024
(1 year, 7 months from now) | |
| EP1628654A2 | UNITED THERAP | Compounds And Methods For Delivery Of Prostacyclin Analogs |
May, 2024
(1 year, 7 months from now) | |
| EP2792353B1 | UNITED THERAP | Polymorph Of Treprostinil Diethanolamine Salt |
May, 2024
(1 year, 7 months from now) | |
| EP2792353A2 | UNITED THERAP | Polymorph Of Treprostinil Diethanolamine Salt |
May, 2024
(1 year, 7 months from now) | |
| EP1628654B2 | UNITED THERAP | Compounds And Methods For Delivery Of Prostacyclin Analogs |
May, 2024
(1 year, 7 months from now) | |
| EP2252570A1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(6 years from now) | |
| EP2252570B1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9278901 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 7 months from now) | |
| US9422223 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 7 months from now) | |
| US8252839 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 7 months from now) | |
| US7544713 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2024
(1 year, 9 months from now) | |
| US9393203 | UNITED THERAP | Osmotic drug delivery system |
Apr, 2026
(3 years from now) | |
| US8410169 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Feb, 2030
(7 years from now) | |
| US8349892 | UNITED THERAP | Solid formulations of prostacyclin analogs |
Jan, 2031
(8 years from now) | |
| US8747897 | UNITED THERAP | Osmotic drug delivery system |
Aug, 2031
(8 years from now) | |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil; A method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; a method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.125MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 0.25MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 1MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 2.5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
2. Drug name - REMODULIN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(6 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(6 years from now) | |
| CN103274926A | UNITED THERAP | Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| CN101903324B | UNITED THERAP | A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method |
Dec, 2028
(6 years from now) | |
| CN101903324A | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| CN103274926B | UNITED THERAP | An Improved Method For Preparing Active Components In The Curved Remodulin |
Dec, 2028
(6 years from now) | |
| IN201003640P4 | UNITED THERAP | An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| IN287697B | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| EP2252570A1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(6 years from now) | |
| EP2252570B1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 7 months from now) | |
| US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(2 years from now) | |
| US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(2 years from now) | |
| US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(2 years from now) | |
| US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(5 years from now) | |
| US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(5 years from now) | |
| US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(6 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension; Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration
Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 1MG/ML | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | Prescription |
| 2.5MG/ML | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | Prescription |
| 5MG/ML | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | Prescription |
| 10MG/ML | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | Prescription |
| 20MG/ML | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | Prescription |
3. Drug name - TYVASO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(6 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(6 years from now) | |
| CN103274926A | UNITED THERAP | Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| CN101903324B | UNITED THERAP | A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method |
Dec, 2028
(6 years from now) | |
| CN101903324A | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| CN103274926B | UNITED THERAP | An Improved Method For Preparing Active Components In The Curved Remodulin |
Dec, 2028
(6 years from now) | |
| IN201003640P4 | UNITED THERAP | An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| IN287697B | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin |
Dec, 2028
(6 years from now) | |
| EP2252570A1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(6 years from now) | |
| EP2252570B1 | UNITED THERAP | An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ® |
Dec, 2028
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
| US10376525 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(4 years from now) | |
| US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(5 years from now) | |
| US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(5 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.6MG/ML | SOLUTION;INHALATION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.